Biologics: Changing the Treatment Scope for Psoriasis and Psoriatic Arthritis: References

References

1. Levy LL, Solomon SM, Emer JJ. Biologics in the treatment of psoriasis and emerging new therapies in the pipeline. Psoriasis: Targets and Therapy. 2012;2:29-43.

2. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35.

3. Han G. In the pipeline for psoriasis: Upcoming psoriasis treatments. Cutis. 2014;93(3):E12-E16.

4. Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in the incidence of adult-onset psoriasis over three decades: A population-based study. J Am Aacd Dermatol. 2009;60(3):394-401.

5. Parisi R, Symmons DR, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385.

6. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850.

7. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851-864.

8. National Psoriasis Foundation. Moderate to Severe Psoriasis: Biologic Drugs. www.psoriasis.org/about-psoriasis/treatments/biologics. Accessed November 5, 2014.

9. Humira [prescribing information]. North Chicago, IL: AbbVie Inc; 2013.

10. Cimzia [prescribing information]. Smyrna, GA: UCB Inc; 2013.

11. Enbrel [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2013.

12. Simponi [prescribing information]. Horsham, PA: Janssen Biotech Inc; 2013.

13. Remicade [prescribing information]. Horsham, PA: Janssen Biotech Inc; 2013.

14. Stelara [prescribing information]. Horsham, PA: Janssen Biotech Inc; 2014.

15. Rustin MH. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. Br J Dermatol. 2012;167(suppl 3):3-11.

16. Menter A, Korman NJ, Elmets CA. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451-485.

17. Kamangar F, Leah I, Bhutani T, et al. How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center. J Dermatolog Treat. 2013;24(1):13-24.

18. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol.

2008;58(1):106-115.

19. Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66(2):241-251.

20. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68(5):702-709.

21. Mease PJ, Fleischmann R, Deodhar R, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48-55.

22. Kivelevitch D, Mansouri B, Menter A. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics. 2014;8:169-182.

23. Ortonne JP, Griffiths C, Daud.n E, et al. Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: The CRYSTEL study. Exp Rev Dermatol. 2008;3(6):657-665.

24. Daud.n E, Griffiths CE, Ortonne JP, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: The CRYSTEL study. J Eur Acad Dermatol Venereol. 2009;23(12):1374-1382.

25. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33(4):712-721.

26. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60(4):976-986.

27. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A Phase III, multicentre, doubleblind trial. Lancet. 2005;366(9494):1367-1374.

28. Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27(12):1535-1545.

29. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780-789.

30. National Psoriasis Foundations. Biologic Drugs: Fact Sheets. www.psoriasis.org/about-psoriasis/treatments/biologics/resources. Accessed November 5, 2014.

31. Schafer JA, Kjesbo NK, Gleason PP. Formulary review of 2 new biologic agents: Tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. J Manag Care Pharm. 2010;16(6):402-416.

32. Chi CC, Wang SH. Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: A meta-analysis and cost-efficacy analysis using the intention-to-treat principle. BioMed Res Int. 2014;2014:862851.

33. van Cranenburgh OD, de Korte J, Sprangers MA, de Rie MA, Smets EM. Satisfaction with treatment among patients with psoriasis: a web-based survey study. Br J Dermatol. 2013;169(2):398-405.

34. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190-1199.

35. Amgen and AstraZeneca announce positive results from phase 3 study of brodalumab (AMG 827) in patients with moderate-to-severe plaque psoriasis [news release]. Thousand Oaks, CA. Amgen Inc; May 9, 2014. www.amgen.com/media/media_pr_detail.jsp?year=2014&releaseID=1929460. Accessed November 5, 2014.